Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.
about
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos inHepatitis C virus-HIV-coinfected patients and liver transplantationNatural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Predictive factors associated with hepatitis C antiviral therapy response.Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.Vanishing bile duct syndrome in human immunodeficiency virus infected adults: a report of two cases.Living-donor liver transplantation and hepatitis CSofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceIs it time to rethink combined liver-kidney transplant in hepatitis C patients with advanced fibrosis?Histopathological evaluation of recurrent hepatitis C after liver transplantation: a reviewPost-transplant liver biopsy and the immune response: lessons for the clinician.Intrahepatic cholestasis in common chronic liver diseases.Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.Hepatitis C virus and liver transplantation: where do we stand?A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Management of Post-Liver Transplant Recurrence of Hepatitis C.Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure.Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C.Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation.New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.HCV in liver transplantation.Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation.Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria.
P2860
Q26777506-5D64130D-05C9-4853-8E24-22E8C11D8E18Q26820811-9EAFACE4-B48A-4F82-A611-06DBCD1F536FQ27011255-9AFD6CA9-9006-4D26-B05A-B1D9002A5C5EQ34093754-8D46F0D5-6C90-4790-B3E2-B5DB516A3E45Q35790397-0AD9E409-DFCB-4073-941B-28E09E6B15FCQ36190835-6A405793-A9FD-4443-A0C3-1D103AD07530Q36525547-51E92A01-0382-4A4A-A799-EAB281E6196FQ36587253-9453CEA4-ABE3-48CB-8801-5B08317391DDQ36587395-21202AF5-D100-4D75-B4C3-6D94D05FCF6BQ36760075-C338B830-7DBC-44E1-9F8A-F6D93E07CABDQ36816846-5D34C5E4-BB27-481B-968B-8CC740287357Q37222388-DD4A5C03-13D4-48EB-9A50-9D287474B8CDQ37349067-98E4E12C-0F6E-4D78-B5DE-E05E5B609381Q37651918-68CA3791-1145-4226-8F55-AFF844BD843FQ37654458-CE82A1AC-E28A-49C2-9C9E-8E2B01E1A98AQ38053173-EC34257D-FFDE-48C9-AEFF-605540BBA05BQ38127461-815F1F6F-E187-4884-B3B8-999C9374D6A1Q38137989-0AF37AE8-82B4-4BAE-BB43-5EDC4962A17AQ38551818-0B8B03DD-11F6-4885-A7C1-8054E984491FQ38578520-69F84CF0-EEF7-43F3-9595-BD6A99F32C88Q38584289-E2A6AD3B-F2D6-4FE7-8AF2-DBB14E79E78CQ38790455-4DF4ECD8-EE0F-4676-A5BE-D9897A63BE9EQ39007700-D345787B-5DDF-4D78-A832-C2B7936B5DECQ39017681-310F6F11-F3DF-46F4-BBF3-ED09FDC30691Q39023015-F872BE59-5C14-4A1D-B574-43FA80FE75DEQ40271222-59C497CC-5295-4977-B12F-4D848FFC4E95Q40322535-21FCCFB9-DBD1-4892-BDD2-41804F59BF38Q40356307-FF468A0E-948C-4CDF-8A59-1657612E6563Q40396755-5DA0A125-F4DE-4A76-98F1-525A18856332Q40420373-F6A0E290-0C3C-4FD8-84F7-950D23932CCCQ40635393-5C2A254B-B025-4530-81B2-D139EA541D82Q41470523-FB66B1F0-73AF-4A61-AD02-6C88C4FD25BFQ41610405-67181E9E-DDA7-4880-A424-0D464CD519CFQ41673507-E54CCEBC-A95C-4BA3-9AC6-84AE676D8445Q42024851-A61CF3BC-4D1E-458D-967F-9C4E99C0595FQ42287044-103267DF-EE24-40B7-8212-E72781653B20Q42982631-D34D4510-895B-4ACA-A0F8-182102236AD3Q42991323-1E98F288-AC48-4110-85CE-CA750FDC12C0Q43716197-719F536E-9C89-49F3-AAA3-D92B4C981425Q44353697-38189FF7-24DF-4E22-ACE7-53AAC8DCCB66
P2860
Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Post-liver transplant cholesta ...... ication of consensus criteria.
@en
Post-liver transplant cholesta ...... ication of consensus criteria.
@nl
type
label
Post-liver transplant cholesta ...... ication of consensus criteria.
@en
Post-liver transplant cholesta ...... ication of consensus criteria.
@nl
prefLabel
Post-liver transplant cholesta ...... ication of consensus criteria.
@en
Post-liver transplant cholesta ...... ication of consensus criteria.
@nl
P2093
P356
P1476
Post-liver transplant cholesta ...... ication of consensus criteria.
@en
P2093
Mark W Russo
Tarun K Narang
Will Ahrens
P304
P356
10.1002/LT.22175
P577
2010-11-01T00:00:00Z